Israël - anglais - Ministry of Health

unipharm ltd, israel - atomoxetine as hydrochloride - coated tablets - atomoxetine as hydrochloride 40 mg - atomoxetine - atomic is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. treatment must be initiated by a specialist in the treatment of adhd, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. diagnosis should be made according to current dsm criteria or the guidelines in icd. in adults, the presence of symptoms of adhd that were pre-existing in childhood should be confirmed. third-party corroboration is desirable and atomic should not be initiated when the verification of childhood adhd symptoms is uncertain. diagnosis cannot be made solely on the presence of one or more symptoms of adhd.based on clinical judgment, patients should have adhd of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.

Israël - anglais - Ministry of Health

unipharm ltd, israel - atomoxetine as hydrochloride - coated tablets - atomoxetine as hydrochloride 60 mg - atomoxetine - atomic is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. treatment must be initiated by a specialist in the treatment of adhd, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. diagnosis should be made according to current dsm criteria or the guidelines in icd. in adults, the presence of symptoms of adhd that were pre-existing in childhood should be confirmed. third-party corroboration is desirable and atomic should not be initiated when the verification of childhood adhd symptoms is uncertain. diagnosis cannot be made solely on the presence of one or more symptoms of adhd.based on clinical judgment, patients should have adhd of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.

Israël - anglais - Ministry of Health

unipharm ltd, israel - olanzapine - film coated tablets - olanzapine 10 mg - olanzapine - acute and maintenance treatment of schizophrenia. zappa is indicated for the management of the manifestations of psychotic disorders. zappa is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder: in patients whose manic episode has responded to olanzapine treatment zappa is indicated for the prevention of reccurence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of zappa with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Israël - anglais - Ministry of Health

unipharm ltd, israel - olanzapine - film coated tablets - olanzapine 5 mg - olanzapine - acute and maintenance treatment of schizophrenia. zappa is indicated for the management of the manifestations of psychotic disorders. zappa is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder: in patients whose manic episode has responded to olanzapine treatment zappa is indicated for the prevention of reccurence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of zappa with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Israël - anglais - Ministry of Health

unipharm ltd, israel - olanzapine - film coated tablets - olanzapine 7.5 mg - olanzapine - acute and maintenance treatment of schizophrenia. zappa is indicated for the management of the manifestations of psychotic disorders. zappa is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.prevention of recurrence in bipolar disorder: in patients whose manic episode has responded to olanzapine treatment zappa is indicated for the prevention of reccurence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of zappa with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Israël - anglais - Ministry of Health

unipharm ltd, israel - buspirone hydrochloride - tablets - buspirone hydrochloride 10 mg - buspirone - for the short-term management of anxiety disorders.

Israël - anglais - Ministry of Health

unipharm ltd, israel - amiodarone hydrochloride - tablets - amiodarone hydrochloride 200 mg - amiodarone - coronary insufficiency, arrhythmias resistant to other treatments.

Israël - anglais - Ministry of Health

unipharm ltd, israel - roxithromycin - tablets - roxithromycin 150 mg - roxithromycin - for the treatment of infections caused by microorganisms sensitive to roxithromycin e.g: ent bronchopulmonary, genital and skin manifestations.

Israël - anglais - Ministry of Health

unipharm ltd, israel - citalopram as hydrobromide - tablets - citalopram as hydrobromide 20 mg - citalopram - for the treatment of states of depression or panic disorder.

Israël - anglais - Ministry of Health

unipharm ltd, israel - citalopram as hydrobromide - tablets - citalopram as hydrobromide 40 mg - citalopram - for the treatment of states of depression or panic disorder.